Dive Brief:

潜水简介：

Ono Pharmaceutical has agreed to buy cancer drugmaker Deciphera Pharmaceuticals in a deal that values the latter company at $2.4 billion.

大野制药（Ono Pharmaceutical）同意收购癌症药物制造商破译制药（Deciphera Pharmaceuticals），该交易对破译制药的估值为24亿美元。

Per deal terms, Ono is purchasing in cash all outstanding shares of Deciphera for $25.60, reflecting a 75% premium to the stock’s closing price Friday. The companies expect to complete their deal sometime between July and September, at which point Deciphera would become a wholly owned subsidiary of Ono..

根据交易条款，小野以25.60美元的价格以现金购买了解密的所有流通股，比该股周五的收盘价溢价75%。两家公司预计在7月至9月之间完成交易，届时破译将成为小野的全资子公司。。

The acquisition would hand Ono a marketed therapy for a type of tumor found in the gastrointestinal tract, as well as a slate of experimental cancer drugs. Of those, the most advanced is a medicine called vimseltinib that last fall succeeded in a key study. Before the end of June, Deciphera plans to submit the medicine for approval as a treatment for a group of rare tumors that affect tissues around the joints..

此次收购将为小野提供一种用于治疗胃肠道肿瘤的市售疗法，以及一系列实验性抗癌药物。其中，最先进的是一种名为vimseltinib的药物，去年秋天在一项关键研究中取得了成功。在6月底之前，Deciphera计划将该药物提交批准，用于治疗一组影响关节周围组织的罕见肿瘤。。

Dive Insight:

潜水洞察：

Ono’s purchase adds to a recent upswing in biopharma deals. According to a database compiled by BioPharma Dive, drugmakers this year have inked at least 16 buyouts worth $50 million or more. The tally is higher than the 11 seen over the same period in 2023.

小野的收购增加了近期生物制药交易的增长。根据BioPharma Dive编制的一个数据库，制药商今年已经签署了至少16份收购协议，价值5000万美元或更多。这一数字高于2023年同期的11个数字。

To Ono, which is based in Japan, the deal announced Monday offers a way to both build out its cancer research and get a stronger foothold in other markets. In a statement, CEO Gyo Sagara noted how the Deciphera acquisition will expand his company’s oncology portfolio as well as accelerate its business development activities in the U.S.

对于总部位于日本的大野来说，周一宣布的协议提供了一种方法，既可以加强其癌症研究，又可以在其他市场获得更强有力的立足点。首席执行官吉奥·萨加拉（GyoSagara）在一份声明中指出，收购Deciphera将扩大其公司的肿瘤学投资组合，并加速其在美国的业务发展活动。

and Europe..

和欧洲。。

Bradley Canino, an analyst who covers Deciphera for the investment bank Stifel, wrote in a note to clients that Ono currently makes around 30% of its revenue from markets in the Americas. Moving forward, though, the U.S. “will become more important due to the ability to command a price premium and recoup R&D costs.”.

投资银行Stifel的Deciphera分析师布拉德利·卡尼诺（BradleyCanino）在给客户的一份报告中写道，小野目前约30%的收入来自美洲市场。然而，展望未来，美国“将变得更加重要，因为它有能力获得价格溢价并收回研发成本。”。

Canino also used the Ono deal to suggest that investors may want to change how they think about companies like Deciphera. He noted how mid-sized drugmakers have shown an appetite for “de-risked” cancer assets, and how “this trend in oncology should not be ignored.” Some examples of that trend include the tie-ups between Sobi and CTI BioPharma, Ipsen and Epizyme, and Genmab and ProfoundBio..

卡尼诺还利用与小野的交易暗示，投资者可能希望改变他们对解密（Deciphera）等公司的看法。他指出，中型制药商如何表现出对“去风险”癌症资产的兴趣，以及“这种肿瘤学趋势不应被忽视”。这种趋势的一些例子包括Sobi和CTI BioPharma、Ipsen和Epizyme以及Genmab和ProfoundBio之间的合作。。

“These deals suggest that companies that can commercialize important, but small, oncology drugs should have the ability to find an acquisition exit amongst a broad suite of acquirers once the commercial market has been established with a successful launch,” the analyst wrote.

这位分析师写道：“这些交易表明，一旦商业市场建立并成功推出，能够将重要但规模较小的肿瘤药物商业化的公司应该有能力在众多收购者中找到收购退出的机会。”。